Abstract: Provided herein are methods, compositions and articles of manufacture for use in connection with cell therapy involving the administration of one or more doses of a therapeutic T cell composition. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the provided embodiments, including the numbers of cells or units of cells administered and/or the potency of administered cells, provide various advantages, such as lower risk of toxicity in subjects administered the T cell compositions.

Abstract: Provided are methods and articles of manufacture for use with cell therapy for the treatment of diseases or conditions, e.g., cancer, including for predicting and treating a toxicity. In some embodiments, the toxicity is a neurotoxicity or cytokine release syndrome (CRS), such as a severe neurotoxicity or a severe CRS. The methods generally involve detecting a marker by assaying a biological sample from a subject that is a candidate for treatment, optionally with a cell therapy, to determine if the subject is at risk for developing the toxicity, such as neurotoxicity or CRS or severe neurotoxicity or severe CRS. In some embodiments, the methods and articles of manufacture further includes a regent for assaying the biological sample and instructions for determining the percentage or number of cells positive for the marker in the biological sample.

Abstract: Techniques are described herein that allow a user equipment (UE) to configure a subcarrier spacing value while monitoring synchronization signals of neighboring cells. In some wireless communication systems, synchronization signals in given radio frequency spectrum band may be transmitted using one of a plurality of different subcarrier spacings. In some cases, a network entity, such as a base station, may transmit an indication to the UE that indicates the subcarrier spacing used by a cell to transmit a specific set of synchronization signals. In some cases, the UE may select a subcarrier spacing based on a database of subcarrier spacings stored locally by the UE. In some cases, the UE may select the subcarrier spacing based on a predetermined configuration.

Abstract: A mobile station that is configured to perform common channel cancellation may include a parameter estimation unit that is configured to estimate parameters for generating a common channel error. The mobile station may also include a common channel generation unit that is configured to generate the common channel error based on the parameters. The mobile station may also include an adder that is configured to subtract the common channel error from received data samples.

Abstract: The present invention is directed to a method for the preparation of macrocyclic compounds of formula (I), comprising the step of cyclizing a diene of formula (II), in the presence of a catalyst, wherein R1-R6, A, W and V are as defined herein. The present invention is also directed to intermediate compounds of formula II.

Abstract: A mobile station that is configured to perform common channel cancellation may include a parameter estimation unit that is configured to estimate parameters for generating a common channel error. The mobile station may also include a common channel generation unit that is configured to generate the common channel error based on the parameters. The mobile station may also include an adder that is configured to subtract the common channel error from received data samples.

Abstract: Techniques for controlling transmit power are described. Due to link imbalance, a downlink (DL) serving cell may have the best downlink for a UE, and an uplink (UL) serving cell may have the best uplink for the UE. In one design of UL power control, the UE receives first and second UL TPC commands from the DL and UL serving cells, respectively, and adjusts its transmit power based on these UL TPC commands and in accordance with an OR-of-the-UPs rule. In one design of DL power control, the UE generates a DL TPC command based on received signal qualities of both the DL and UL serving cells. In another design, power control is performed independently for the DL and UL serving cells. The UE generates a separate DL TPC command for each cell, which adjusts its transmit power based on the DL TPC command for that cell.

Abstract: Disclosed is a process of making compounds of formula(I): wherein R1, R2, R3, R4 and Ra of formula(I) are defined herein. The product compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation. Also disclosed are intermediates useful in making such compounds.

Abstract: A process for stereoselective synthesis of a compound of Formula (I) wherein R1, R2, R3, R4, and R5 are as described herein.

Abstract: Disclosed is a process for preparing a compound of formula I comprising cyclizing a diene compound of formula III in the presence of a ruthenium catalyst in a suitable organic solvent, wherein the process is performed in a gaseous fluid at supercritical or near-supercritical conditions: The compounds of formula (I) are active agents for the treatment of hepatitis C viral (HCV) infections or are intermediates useful for the preparation of anti-HCV agents.

Abstract: Disclosed is a process for preparing a macrocyclic compound of the formula (I) wherein a hydroxyl-substituted macrocyclic compound of formula (3) is reacted with a sulfonyl-substituted compound of formula QUIN: The compounds of formula (I) are potent active agents for the treatment of hepatitis C virus (HCV) infection.

Abstract: Disclosed is a process for preparing a compound of formula I comprising cyclizing a diene compound of formula III in the presence of a ruthenium catalyst in a suitable organic solvent, wherein the process is performed in a gaseous fluid at supercritical or near-supercritical conditions: The compounds of formula (I) are active agents for the treatment of hepatitis C viral (HCV) infections or are intermediates useful for the preparation of anti-HCV agents.

Abstract: A process for stereoselective synthesis of a compound of Formula (I) wherein R1, R2, R3, R4, and R5 are as described herein.

Abstract: Disclosed is a multi-step process for preparing a macrocyclic compound of the formula (I): wherein Q is a radical of the following formula: and the other variables are as defined herein. The compounds of formula (I) are potent active agents for the treatment of hepatitis C virus (HCV) infection.

Abstract: A process for removing ruthenium or ruthenium-containing compounds from a reaction mixture comprising a compound of the following formula I in an organic solvent using supercritical fluid processing techniques: wherein RA, R3, R4, D and A are as defined herein. This invention has particular application for removing ruthenium-containing catalyst and ruthenium-containing catalyst by products from reaction mixtures that result from ring-closing olefin metathesis (RCM) reactions.

Abstract: A process for stereoselective synthesis of compounds of Formula X wherein: R1 is an aryl or heteroaryl group, each optionally independently substituted with one to three substituent groups, wherein each substituent group of R1 is independently C1-C5 alkyl, C2-C5 alkenyl, C2-C5 alkynyl, C3-C8 cycloalkyl, heterocyclyl, aryl, heteroaryl, C1-C5 alkoxy, C2-C5 alkenyloxy, C2-C5 alkynyloxy, aryloxy, C1-C5 alkanoyloxy, C1-C5 alkanoyl, aroyl, trifluoromethyl, trifluoromethoxy, or C1-C5 alkylthio, wherein each substituent group of R1 is optionally independently substituted with one to three substituent groups selected from methyl, methoxy, fluoro, chloro, hydroxy, oxo, cyano, or amino; and R2 and R3 are each independently hydrogen or C1-C5 alkyl, or R2 and R3 together with the carbon atom they are commonly attached to form a C3-C8 spiro cycloalkyl ring.

Abstract: Disclosed is a process for preparing a macrocyclic compound of the formula (I): which is carried out using an intermediate of the formula (II): wherein W, R1 through R4, D, A and R12 are as defined herein. The compounds of formula (I) are potent active agents for the treatment of hepatitis C virus (HCV) infection.

Abstract: Disclosed is a process of making compounds of formula(I): 1

Abstract: Disclosed is a novel method of producing heteroaryl amines of the formula(I): wherein X, Y and Z are described herein, the heteroarylamines are useful in the production of heteroaryl ureas which are key component in pharmaceutically active compounds possessing a heteroaryl urea group.

Abstract: Disclosed is a novel method of producing heteroaryl amines of the formula(I): 1